Gsk (GSK) Short term Debt (2015 - 2026)

Gsk (GSK) has 12 years of Short term Debt data on file, last reported at -$7.3 billion in Q2 2026.

• For the quarter ending Q2 2026, Short term Debt changed 0.11% year-over-year to -$7.3 billion; the trailing twelve-month figure through Jun 2026 stood at -$7.3 billion (changed 0.11% YoY), and the FY2025 full-year result was -$7.2 billion, up 8.26% from the prior year.
• Short term Debt was -$7.3 billion for Q2 2026 at Gsk, down from -$7.1 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of -$6.6 billion in Q2 2023 to a low of -$7.8 billion in Q4 2024.
• A 5-year average of -$7.2 billion and a median of -$7.2 billion in 2025 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt retreated 15.44% in 2024 and advanced 8.63% in 2025, its largest moves.
• Gsk's Short term Debt stood at -$6.8 billion in 2022, then decreased by 2.7% to -$7.0 billion in 2023, then decreased by 12.61% to -$7.8 billion in 2024, then increased by 8.63% to -$7.2 billion in 2025, then decreased by 1.24% to -$7.3 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were -$7.3 billion in Q2 2026, -$7.1 billion in Q1 2026, and -$7.2 billion in Q4 2025.